EDWARDS LIFESCIENCES CORP

Edwards Lifesciences dominates the minimally invasive heart‑valve market with proven safety, 90%+ 5‑year durability, and a positive one‑year ROI, making it a top choice for investors and clinicians alike.

Edwards Lifesciences invests €10 m in Carvolix, a French AI‑driven cardiac robotics start‑up, aiming to boost next‑gen cardiovascular tech and unlock new revenue streams amid evolving FDA rules and stiff competition.

Edwards Lifesciences ends EU antitrust probe, lifting regulatory risk and boosting Q1 earnings—key for investors eyeing cardiovascular device growth.

Edwards Lifesciences announces Feb 10 earnings call & TD Cowen healthcare conference, revealing stable shares, new TAVR advances and investor confidence.

Edwards Lifesciences investor focus: spectrum asset sale, FTC antitrust ruling and heart‑valve growth insights.

FTC blocks Edwards Lifesciences’ JenaValve deal, slashing growth prospects and shaking investor confidence as the company pivots to new strategies in a tightening cardiovascular market.

FTC blocks Edwards Lifesciences’ bid for JenaValve, halting a key TAVR deal and shaking investor sentiment while the company’s core valve business remains strong.

Edwards Lifesciences faces FTC scrutiny over its $945 million JenaValve acquisition, amid antitrust concerns and market‑watching optimism about future TAVR growth.

Edwards Lifesciences: rising stock, strong valve market share, but regulatory and supply‑chain risks—how the company’s innovation pipeline and digital health gains could drive future growth.

Edwards Lifesciences drives premium growth in heart‑valve tech, with strong pipelines, high margins and expanding reimbursement boosting investor confidence.